Abstract
Receptive anal intercourse (RAI) may substantially increase HIV acquisition risk per sex act compared to receptive vaginal intercourse (RVI). To understand how levels of RAI change over time and evaluate the impact of exposure definitions for RAI on HIV incidence, we analysed three prospective HIV cohorts of women: RV217, MTN-003 (VOICE), and HVTN 907. At baseline 16.0% (RV 217), 17.5% (VOICE) of women reported RAI in the past 3 months and 27.3% (HVTN 907) in the past 6 months, with RAI declining during follow-up by around 3-fold. Hazard ratios, adjusted for potential confounders (aHR), indicate that reporting RAI at baseline increased HIV incidence in the three cohorts: 1.1 (95% Confidence interval: 0.8-1.5) for VOICE, aHR of 3.3 (1.6-6.8) for RV 217, and 1.9 (0.6-6) for HVTN 907. Using time-varying exposure definition slightly increased the estimated association for VOICE (aHR=1.2; 0.9-1.6), however reporting >30% RAI sex acts during VOICE follow-up was not associated with higher HIV incidence (aHR=0.7 (0.4-1.1)). Women who always reported RAI during follow-up where also at increased HIV acquisition risk. Overall, we found that precisely estimating RAI and HIV association after multiple RVI/RAI exposures is sensitive to RAI exposure definitions and may be influenced by measurement errors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported by the HPTN Modelling Centre, which is funded by the U.S. National Institutes of Health (NIH UM1 AI068617) through HPTN. RS and MCB acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. MTN 003 (VOICE): funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health RV 217: This work was supported by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research was funded, in part, by the U.S. National Institute of Allergy and Infectious Diseases. Material has been reviewed by the Walter Reed Army Institute of Research. The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense, or HJF. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25. HVTN 907: This research was supported by the HIV Vaccine Trials Network, which is funded through a cooperative agreement with the Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, grants UO1AI068614, UO1AI068635, UO1AI068618, U01AI069415, 5U01AI069421, and 5U01AI069486. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health Award [Grant Numbers R01AI057020 and UM1AI068619]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics commitee of Imperial College London gave ethical approval for this work (#16IC3667)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations
Funding This work was partly supported by the HPTN Modelling Centre, which is funded by the U.S. National Institutes of Health (NIH UM1 AI068617) through HPTN. RS and MCB acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.
MTN 003 (VOICE): funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health RV 217: This work was supported by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). This research was funded, in part, by the U.S. National Institute of Allergy and Infectious Diseases. Material has been reviewed by the Walter Reed Army Institute of Research. The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense, or HJF. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25.
HVTN 907: This research was supported by the HIV Vaccine Trials Network, which is funded through a cooperative agreement with the Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, grants UO1AI068614, UO1AI068635, UO1AI068618, U01AI069415, 5U01AI069421, and 5U01AI069486.
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health Award [Grant Numbers R01AI057020 and UM1AI068619]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention.
Conflicts of interest The authors have no conflicts of interest to disclose. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Ethics approval Ethics approval was obtained from for VOICE, for RV 217, and for HVTN 907. Further ethics approval was obtained from Imperial College London (approval # 16IC3667).
Availability of data and material The data and material analysed can be obtained following specific procedures.
Code availability The code used for the presented analysis is available for review upon request.
Data Availability
The data and material analysed can be obtained following specific procedures.